Novartis seeks European approval for once-daily Galvus for treatment of type 2 diabetes

By Lisa Kerner

Charlotte, N.C., Aug. 17 - Novartis AG submitted its new, once-daily oral therapy Galvus (vildagliptin) for European approval for the treatment of type 2 diabetes.

Galvus has demonstrated blood sugar lowering effects, even among patients who have poor glycemic control, are obese or older than 65, without associated weight gain, according to a company news release.

The therapy's novel mechanism of action targets the pancreatic islet dysfunction that causes high blood sugar levels in people with type 2 diabetes.

Novartis based its Galvus E.U. regulatory submission on a clinical development program containing data from more than 5,400 patients.

Galvus was accepted for U.S. regulatory review in March, the company said.

Novartis is a Basel, Switzerland, pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.